A detailed history of Beacon Pointe Advisors, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 4,000 shares of SRPT stock, worth $489,320. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,000
Previous 4,022 0.55%
Holding current value
$489,320
Previous $520,000 21.54%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$113.33 - $163.85 $2,493 - $3,604
-22 Reduced 0.55%
4,000 $632,000
Q1 2024

May 14, 2024

SELL
$93.7 - $141.53 $213,823 - $322,971
-2,282 Reduced 36.2%
4,022 $520,000
Q4 2023

Feb 08, 2024

SELL
$67.31 - $124.76 $31,164 - $57,763
-463 Reduced 6.84%
6,304 $607,000
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $35,670 - $43,009
-348 Reduced 4.89%
6,767 $820,000
Q2 2023

Aug 11, 2023

SELL
$106.4 - $157.19 $35,963 - $53,130
-338 Reduced 4.54%
7,115 $814,000
Q1 2023

May 12, 2023

SELL
$117.53 - $155.99 $303,227 - $402,454
-2,580 Reduced 25.72%
7,453 $1.03 Million
Q4 2022

Feb 14, 2023

SELL
$100.86 - $132.13 $49,623 - $65,007
-492 Reduced 4.67%
10,033 $1.3 Million
Q3 2022

Nov 09, 2022

BUY
$75.71 - $119.24 $15,899 - $25,040
210 Added 2.04%
10,525 $1.16 Million
Q2 2022

Aug 11, 2022

SELL
$62.69 - $88.44 $118,672 - $167,416
-1,893 Reduced 15.51%
10,315 $771,000
Q1 2022

May 17, 2022

BUY
$63.15 - $90.42 $164,505 - $235,544
2,605 Added 27.13%
12,208 $954,000
Q4 2021

Feb 14, 2022

SELL
$77.28 - $99.42 $428,131 - $550,786
-5,540 Reduced 36.58%
9,603 $865,000
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $817,368 - $1.15 Million
12,390 Added 450.05%
15,143 $1.4 Million
Q2 2021

Aug 17, 2021

BUY
$69.38 - $86.75 $191,003 - $238,822
2,753 New
2,753 $214,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Beacon Pointe Advisors, LLC Portfolio

Follow Beacon Pointe Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beacon Pointe Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beacon Pointe Advisors, LLC with notifications on news.